Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer
Clinical and Molecular Hepatology · 01.04.2025 · 31 (2) · 350-381
DOI: 10.3350/cmh.2024.0857 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2025. Verfasst von Chenyang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Liver Neoplasms, Liver. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, Tongji Hospital (Huazhong University of Science and Technology) Foundation for Excellent Young Scientist.
Abstract (Originalsprache)
The trillions of commensal microorganisms living in the gut lumen profoundly influence the physiology and pathophysiology of the liver through a unique gut-liver axis. Disruptions in the gut microbial communities, arising from environmental and genetic factors, can lead to altered microbial metabolism, impaired intestinal barrier and translocation of microbial components to the liver. These alterations collaboratively contribute to the pathogenesis of liver disease, and their continuous impact throughout the disease course plays a critical role in hepatocarcinogenesis. Persistent inflammatory responses, metabolic rearrangements and suppressed immunosurveillance induced by microbial products underlie the pro-carcinogenic mechanisms of gut microbiota. Meanwhile, intrahepatic microbiota derived from the gut also emerges as a novel player in the development and progression of liver cancer. In this review, we first discuss the causes of gut dysbiosis in liver disease, and then specify the pivotal role of gut microbiota in the malignant progression from chronic liver diseases to hepatobiliary cancers. We also delve into the cellular and molecular interactions between microbes and liver cancer microenvironment, aiming to decipher the underlying mechanism for the malignant transition processes. At last, we summarize the current progress in the clinical implications of gut microbiota for liver cancer, shedding light on microbiota-based strategies for liver cancer prevention, diagnosis and therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Clinical Medical Research Center of Hepatic Surgery at Hubei Province, Wuhan, China.
- Hubei Key Laboratory of Hepato-Pancreatic-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Key Laboratory of Cancer Invasion and Metastasis (Ministry of Education), Hubei Key Laboratory of Tumor Invasion and Metastasis, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wu…
- Key Laboratory of Organ Transplantation, Ministry of Education, Chinese Academy of Medical Sciences; NHC Key Laboratory of Organ Transplantation, Wuhan, China.
- Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Förderung
- National Natural Science Foundation of China
- Tongji Hospital (Huazhong University of Science and Technology) Foundation for Excellent Young Scientist
Zitieren
APA
Li, C., Cai, C., Wang, C., Chen, X., Zhang, B., & Huang, Z. (2025). Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer. Clinical and Molecular Hepatology, 31(2), 350-381. https://doi.org/10.3350/cmh.2024.0857
Vancouver
Li C, Cai C, Wang C, Chen X, Zhang B, Huang Z. Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer. Clinical and Molecular Hepatology. 2025;31(2):350-381. doi:10.3350/cmh.2024.0857
BibTeX
@article{Li2025,
author = {Li, Chenyang and Cai, Chujun and Wang, Chendong and Chen, Xiaoping and Zhang, Bixiang and Huang, Zhao},
title = {Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer},
journal = {Clinical and Molecular Hepatology},
year = {2025},
volume = {31},
number = {2},
pages = {350--381},
doi = {10.3350/cmh.2024.0857}
}
EUVIMED